Innovent Biologics announces positive Phase 2 results for Efdamrofusp Alfa in nAMD
In an important development for the treatment of neovascular age-related macular degeneration (nAMD), Innovent Biologics, Inc., a leading biopharmaceutical company, has announced successful results from ... Read More
Astellas Pharma to acquire avacincaptad pegol developer Iveric Bio for $6bn
Japanese pharma company Astellas Pharma has agreed to acquire Nasdaq-listed Iveric Bio in an all-cash deal worth around $5.9 billion with an aim to create ... Read More
Kodiak Sciences’ KSI-301 fails to meet primary endpoint in wet AMD trial
Kodiak Sciences said that its antibody biopolymer conjugate KSI-301 failed to meet the primary endpoint in a phase 2b/3 clinical trial in neovascular (wet) age-related ... Read More
Novartis to acquire ocular gene therapy company Gyroscope Therapeutics
Novartis has agreed to acquire Gyroscope Therapeutics, a UK-based ocular gene therapy company, in a deal worth up to $1.5 billion. As per the terms ... Read More
HMR59 : Janssen acquires rights to geographic atrophy treatment candidate from Hemera
Geographic atrophy treatment : Janssen Pharmaceuticals has signed a licensing deal to acquire rights to HMR59, an investigational gene therapy for geographic atrophy, from clinical ... Read More
KSI-301 phase 1b trial : Kodiak Sciences reports new safety, efficacy, and durability data
KSI-301 phase 1b trial : Kodiak Sciences said that its ongoing phase 1b clinical trial of its intravitreal anti-VEGF antibody biopolymer conjugate KSI-301 for the ... Read More
Novartis bags Beovu FDA approval for wet AMD
Beovu FDA approval for wet AMD : Swiss pharma giant Novartis has been given approval from the US Food and Drug Administration (FDA) for Beovu ... Read More